Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials

Transplant Cell Ther. 2021 Feb;27(2):105-107. doi: 10.1016/j.jtct.2020.12.004. Epub 2020 Dec 17.

Authors

Peter A Riedell¹, Justin P Kline², Jacklyn M Gideon², Amittha Wickrema², Michael R Bishop²

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois. Electronic address: priedell@medicine.bsd.uchicago.edu.
² Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois.

PMID: 33781544
DOI: 10.1016/j.jtct.2020.12.004

No abstract available

Keywords: Apheresis; Chimeric antigen receptor T cell therapy; Clinical trials; Early-phase trials; Phase I.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Blood Component Removal*
Immunotherapy, Adoptive
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen